Ceremorphic Life unveils drug discovery platform
image for illustrative purpose
Hyderabad: Ceremorphic Life Sciences showcased its innovative BioCompDiscoverX supercomputing platform at the AI Driven Drug Discovery Summit in Boston.
This cutting-edge platform integrates proprietary analog, quantum, and AI technologies, empowering Ceremorphic Life Sciences, a division of Ceremorphic, Inc., to expedite drug development, reduce costs, accelerate time-to-market, and enhance overall efficacy.
The BioCompDiscoverX will be available in the third quarter of 2024 and will include technologies incorporated in its proprietary silicon device. Using this platform, Ceremorphic Life Sciences plans to develop pharmaceuticals and oversee the essential clinical trials. “With drug discovery becoming slower and more expensive over time, the BioCompDiscoverX platform will allow us to explore the early stages of drug discovery faster and more accurately in order to develop drugs at a rapid rate,” said Dr Venkat Mattela, Founder and CEO of Ceremorphic.
